About AREXVY

AREXVY is the world's first vaccine used to help prevent lung and lower airway infection from respiratory syncytial virus (RSV) in people 60 years and older.1,2

Effective Against RSV

In a clinical study, AREXVY was:

OVER 82%

EFFECTIVE

in preventing lung and lower airway infection from RSV in people aged 60 years and older*1

Overall efficacy in people ≥ 60 years old (n=12466): 82.6%
(96.95% CI: 57.9 to 94.1)

OVER 94%

EFFECTIVE

in preventing lung and lower airway infection from RSV in people aged 60 years and older with asthma, diabetes, chronic obstructive pulmonary disease (COPD), chronic heart failure, advanced liver or kidney disease, or any chronic respiratory or pulmonary disease*1

Efficacy in participants with ≥1 comorbidity of interest (n=4937): 94.6%
(95% CI: 65.9 to 99.9)

*In a clinical study

For Those 60 Years and Older

AREXVY helps to protect people 60 years and older — including those with certain health conditions (see above) — from lung and lower airway infections from RSV.1

Elder women smiling

AREXVY is available for people aged 60 and older

quadrivalent flu vaccine

AREXVY can be given at the same time as an inactivated unadjuvanted quadrivalent flu vaccine

single-dose shot

AREXVY is given as a single-dose shot

How Does AREXVY Work?

AREXVY boosts your body's protection against RSV, which can cause lower respiratory tract disease (LRTD). AREXVY is purposefully designed to stimulate the immune response to protect against RSV in people aged 60 years and older.1

An Aging Immune System

As people reach older age, the immune system may weaken, and the body can have a more difficult time defending against infections like RSV.3-5

Get questions to ask your doctor about AREXVY FAQs

Safety and side effects

Who Should Not Get AREXVY?

You should not receive AREXVY if you are allergic to any of its ingredients.1

What Are the Potential Side Effects of AREXVY?

  • The most common side effects are injection site pain, fatigue, muscle pain, headache, and joint pain1,8

Additional Important Information:

  • Vaccination with AREXVY may not result in protection of all vaccine recipients
  • Ask your healthcare provider about the risks and benefits of AREXVY. Only a healthcare provider can decide if AREXVY is right for you
  • Fainting can occur following, or even before, any needle injection.1
  • People with weakened immune systems may have reduced immune responses to AREXVY1

Need More Information?

This is only a summary of important information. To learn more about AREXVY, talk to your doctor, or other healthcare provider.

Get questions to ask your doctor about AREXVY FAQs

Ask your doctor about

IMPORTANT SAFETY INFORMATION:1

You should not be given AREXVY if you are allergic to any of its ingredients.

The most common side effects are injection site pain, fatigue, muscle pain, headache, and joint pain.

Vaccination with AREXVY may not result in protection of all vaccine recipients.

Ask your healthcare provider about the risks and benefits of AREXVY. Only a healthcare provider can decide if AREXVY is right for you.

References:
  1. GlaxoSmithKline New Zealand. AREXVY Data Sheet. GSK NZ; 2024. Available at https://www.medsafe.govt.nz/profs/datasheet/a/Arexvyinj.pdf (Last Accessed May 2024)
  2. GSK;2023;1-9;US FDA approves GSK's Arexvy
  3. CDC;2022;1-2;RSV in Older Adults and Adults with Chronic Medical Conditions
  4. Walsh EE;Clinics in chest medicine;2017;38;29-36
  5. Kaler J;Cureus;2023;15;1-17
  6. ESR;2023;1-37;RECOMMENDATION FOR SEASONAL INFLUENZA VACCINE COMPOSITION FOR NEW ZEALAND FOR 2024
  7. GlaxoSmithKline New Zealand. AREXVY Consumer Medicine Information (CMI). GSK NZ; 2024. Available at https://www.medsafe.govt.nz/consumers/cmi/a/Arexvy.pdf
  8. Papi A;N Engl J Med;2023;388;595-608

AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older. AREXVY is a prescription medicine; it is not funded and charges will apply. A single dose (0.5 mL) contains 120 micrograms of RSVPreF3 antigen adjuvanted with AS01E, composed of the plant extract Quillaja saponaria Molina, fraction 21 (QS-21) (25 micrograms) and 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from Salmonella minnesota (25 micrograms). AREXVY should not be administered if you are hypersensitive to any component of this vaccine. AREXVY has risks and benefits - ask your doctor if AREXVY is right for you. Use strictly as directed. Side effects include: joint pain, injection site reactions including pain, swelling and redness, headache, runny nose, fatigue, fever and chills. This is not a full list. Vaccination with AREXVY may not fully protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. Normal doctor's charges apply. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2024 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.

This website is intended for residents of New Zealand only.

Any information provided on this website should be discussed with a healthcare professional and does not replace a healthcare professional's advice.